1
Clinical Trials associated with V3G CH848 Pr-NP1 / Active, not recruitingPhase 1IIT A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Ferritin Nanoparticles Expressing Native-like HIV-1 Envelope Trimers Followed by Boost With mRNA Lipid Nanoparticles Encoding a Native-like HIV-1 Envelope Trimer in Adults Without HIV
This first-in-human (FIH) phase 1 clinical trial will evaluate a prime-boost regimen of immunogens designed to induce HIV-1 Env V3-glycan-specific broadly neutralizing antibodies (V3G bNAbs). The priming immunogen (V3G CH848 Pr-NP1) consists of ferritin NPs expressing 8 copies of an Env trimer. This immunogen will be boosted with an mRNA LNP (V3G CH848 mRNA-Tr2), encoding a soluble Env trimer which does not utilize the ferritin NP design.
100 Clinical Results associated with V3G CH848 Pr-NP1
100 Translational Medicine associated with V3G CH848 Pr-NP1
100 Patents (Medical) associated with V3G CH848 Pr-NP1
100 Deals associated with V3G CH848 Pr-NP1